Business context and reporting period
So-Young International Inc. filed this Form 20-F for the fiscal year ended December 31, 2022; it is an annual report, not a standalone 2022 fourth-quarter filing. The company operates a Chinese online medical-aesthetics content and booking platform, expanded into branded offline treatments in 2022, and sells medical-beauty equipment through Wuhan Miracle, acquired in 2021. Financial statements are prepared under U.S. GAAP; amounts below are RMB unless stated otherwise.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | RMB1,257.9 million (US$182.4 million) | RMB1,692.5 million |
| Gross profit / margin | RMB864.6 million / 68.7% | RMB1,364.6 million / 80.6% |
| Operating loss | RMB102.8 million | RMB32.6 million |
| Net loss attributable to So-Young | RMB65.6 million (US$9.5 million) | RMB8.4 million |
| Operating cash flow | Used RMB112.9 million | Provided RMB84.3 million |
| Cash, cash equivalents and restricted cash at year-end | RMB701.0 million (US$101.6 million) | RMB1,343.8 million |
Term deposits and short-term investments were RMB876.0 million at year-end, in addition to cash and restricted cash. Current assets were RMB1,916.8 million and current liabilities RMB538.0 million. The filing reports no conventional borrowings in the consolidated balance sheet; operating lease liabilities totaled RMB71.3 million. The company said existing liquidity and anticipated operating cash flows should cover working capital and capital expenditures for at least 12 months.
Material changes versus the prior comparable period
- Revenue fell 25.7%. Information services and other revenue declined 31.9% to RMB888.5 million; reservation revenue declined 53.4% to RMB128.7 million. Equipment and maintenance revenue rose to RMB240.7 million from RMB112.0 million.
- Management attributed weaker revenue to lower average revenue per paying provider, fewer providers subscribing to information services, COVID-related restrictions and disruption, and higher subsidies to end users for reservations. Purchasing users fell 28.8% to 396,200; average revenue per paying provider fell 40.0%.
- Gross margin contracted 11.9 percentage points, partly reflecting the equipment business and higher cost of revenue following Wuhan Miracle’s consolidation. Gross profit fell 36.6%.
- Sales and marketing expense declined 40.4% to RMB472.1 million, mainly on lower branding and user-acquisition spending. General and administrative expense rose 3.2% to RMB260.2 million; research and development expense fell 18.0% to RMB235.1 million.
- Net loss widened from RMB37.6 million to RMB66.1 million, while operating cash flow shifted from a positive RMB84.3 million to an outflow of RMB112.9 million. Investing cash outflow was RMB572.2 million, including purchases of investments and term deposits, partly offset by maturities.
Outlook, risks, contingencies and unusual items
- Outlook: No numerical revenue or earnings guidance is provided. Management described plans to build user trust, improve provider digital tools and operating efficiency, expand standardized non-surgical treatments, and grow across consumption-healthcare categories. It cautioned that pandemic effects, consumer demand and market recovery remained uncertain.
- China structure and cash access: The Cayman Islands parent has no direct equity ownership in the VIEs and depends on contractual arrangements to control them. VIEs generated 79.9% of 2022 revenue. Their arrangements are legally uncertain, and restrictions on currency conversion, dividends and cross-border transfers may limit access to operating cash.
- Regulatory exposure: The company disclosed it had not obtained an Audio-Visual License for certain live and video services, though related revenue was described as insignificant. It also flagged evolving rules on medical advertising, online medical services, data privacy, cybersecurity and overseas listings. The So-Young app, removed from app stores in November 2021 over personal-information collection, was reinstated in April 2022 after remediation.
- Audit and listing: The PCAOB vacated its China inspection restriction in December 2022; the company did not expect identification under the HFCAA after this filing, but future access may change. Management and the auditor reported effective internal control over financial reporting as of year-end.
- Legal matters: The filing reports 50 pending platform-related intellectual-property lawsuits with approximately RMB4.7 million in claimed damages, and RMB6.0 million paid or payable in 2022 in settlements or adverse judgments. Management said no unresolved matter was expected to have a material adverse effect. Accrued litigation liabilities were RMB3.6 million at year-end.
- Goodwill and investments: No goodwill impairment was recorded in 2022; RMB540.0 million of goodwill related to Wuhan Miracle. The auditor identified its impairment assessment as a critical audit matter because it depended on projected revenue, operating results and discount-rate assumptions. The company also recorded RMB7.9 million of investment impairment and RMB17.2 million of equity-method losses.
- Capital allocation and governance: The company repurchased 2.05 million ADSs for approximately US$2.2 million in 2022. The 2022 repurchase authorization was increased from US$15 million to US$25 million in January 2023. Xing Jin held 84.5% of voting power; the company does not expect to pay dividends in the foreseeable future.
Important facts for investors to verify
- Whether provider spending, purchasing users and reservation activity recover after the 2022 declines, and whether information-service revenue stabilizes.
- Whether the lower gross margin persists as equipment sales and offline treatment initiatives develop, including Wuhan Miracle’s profitability and goodwill valuation assumptions.
- Cash-flow trajectory and the accessibility of cash held in China and by VIEs, including restrictions on transfers and distributions.
- Current status of VIE enforceability, required licenses and any applicable CSRC filing or cybersecurity-review obligations.
- Updates to pending litigation, app-store compliance and data-protection controls, and the PCAOB’s continuing ability to inspect the auditor.
- Repurchases completed under the expanded authorization, related cash use, and any dilution from outstanding share plans.